Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A low-dose sublingual formulation of Zolpidem has been approved by the FDA for the management of middle-of-the-night (MOTN) awakening. Zolpidem, marketed as Ambien, was originally approved in 1992. The new formulation is marketed by Transcept Pharmaceuticals as Intermezzo.

Zolpidem Tartrate Sublingual Tablets (Intermezzo®) CIV